Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Senti Biosciences logo — Outsmarting complex diseases with more intelligent medicines

Senti Biosciences

Outsmarting complex diseases with more intelligent medicines

Founded 2016 United States South San Francisco, United States 66 employees Grant Total: $223.90M Biotechnology, Health Care +1

General Information

Company Name Senti Biosciences
Founded Year 2016
Location United States South San Francisco, United States +1
Employees 66
Industries Biotechnology, Health Care, Health and Wellness
Funding Stage Grant
Social

Get notified when Senti Biosciences moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Senti Biosciences

Senti Biosciences is a biotechnology startup with a mission to create a new generation of smarter medicines, as reflected in their slogan, "Outsmarting complex diseases with more intelligent medicines." The company was founded in 2016 and is headquartered in the United States. Senti Biosciences is focused on leveraging synthetic biology to develop innovative solutions in the biotechnology and healthcare industries. Their approach involves building a synthetic biology platform to program next-generation cell and gene therapies using "gene circuits," which are novel combinations of DNA sequences. These gene circuits are designed to reprogram cells with biological logic, enabling them to sense inputs, compute decisions, and respond to their cellular environments. Senti Biosciences aims to enhance the therapeutic effectiveness of cell and gene therapies against complex diseases that conventional medicines struggle to address. The company has garnered significant investor interest, with their most recent post-IPO equity investment amounting to a substantial $50.60M, which was secured on 09 June 2022. Notable investors in this round include New Enterprise Associates, Pear Ventures, 8VC, Amgen Ventures, Morgan Stanley Private Equity Asia, Invus, T. Rowe Price, Leaps by Bayer, and the Parker Institute for Cancer Immunotherapy. Overall, Senti Biosciences is pioneering the development of intelligent medicines through synthetic biology, positioning itself at the forefront of innovation in the biotechnology and healthcare sectors. For more information, interested parties can visit the Senti Bio website at https://www.sentibio.com.

Taxonomy: synthetic biology, cell therapy, gene therapy, biological logic, disease treatment, smart medicine, gene circuits, DNA sequences, complex diseases, therapeutic effectiveness, medical innovation

Funding Rounds & Investors (11)

View All
Funding Stage Amount Investors Lead Investors Date
Grant •••••• 1 •••• •••• 01 Jul 2024
Post-IPO Equity •••••• 9
Investor Investor Investor Investor Investor Investor Investor Investor
•••• •••• 		09 Jun 2022
Convertible Note •••••• 1
Investor
24 May 2022
Grant •••••• 1 •••• •••• 28 Sep 2021
Series B •••••• 2
Investor Investor
14 May 2021

View All 11 Funding Rounds

Senti Biosciences Alternatives & Competitors

Senti Biosciences vs
Abeona Therapeutics
Abeona Therapeutics United States

Working together to find a cure

IPO
238 employees
Biotechnology, Health Care
Compare Senti Biosciences vs Abeona Therapeutics
Senti Biosciences vs
LogicBio Therapeutics
LogicBio Therapeutics United States

Develops gene therapy vectors for previously incurable genetic and infectious diseases including hem...

Acquired
13 employees
Biotechnology
Compare Senti Biosciences vs LogicBio Therapeutics
Senti Biosciences vs
Kelonia Therapeutics
Kelonia Therapeutics United States

Revolutionizing in vivo gene delivery to usher in a new era of genetic medicines.

Private Equity
74 employees
Biotechnology, Health Care
Compare Senti Biosciences vs Kelonia Therapeutics

FAQ About Senti Biosciences

Outsmarting complex diseases with more intelligent medicines
Senti Biosciences was founded in 2016.
Senti Biosciences is headquartered in South San Francisco, United States.
Senti Biosciences operates in the following industries: Biotechnology, Health Care, Health and Wellness.
Senti Biosciences has approximately 66 employees.
Senti Biosciences has completed 11 funding rounds, raising a total of $223.90M. The latest funding stage is Grant.
Top alternatives and competitors to Senti Biosciences include Abeona Therapeutics, LogicBio Therapeutics, Kelonia Therapeutics, Taysha Gene Therapies, American Gene Technologies® International Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Senti Biosciences and Abeona Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Senti Biosciences and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy